---
title: Antithrombotics
author: J. Austin Straley, DO
layout: post
date: 2023-03-30
published: true
permalink: /antithrombotics
resource: true
categories: [Blood & Anti-Inflammatories]
---
---

- 1) Antiplatelet Drugs
  - COX Inhibitors
    - Acetylsalicylic Acid (Aspirin)
      - COX1 Inhibition (Thromboxane A2)
      - COX2 Inhibition at high doses
      - Overdose:
        - Gastric Lavage, Activated Charcoal
        - Alkalinization of the urine (IV Sodium Bicarb)
          - Goal of urine pH ≥7.5
        - Dialysis if Salicylate levels ≥90-100 with acute intoxication or ≥60 ng/mL in chronic administration
  - ADP Receptor Antagonists (P2Y12 Inhibitors)
    - Binds platelet ADP receptor
      - Inhibits platelet aggregation
      - Used in aspirin intolerant or in coronary stents
    - Require CYP450 activation
      - Clopidogrel (Plavix)
      - Prasugrel (Effient, 10x stronger, more rapid)
        - More bleeding risk than clopidogrel
        - CI in ≥75 y/o, renal impaired, CVD
      - Ticlopidine
    - Nucleotide/Nucleoside Analogs
      - Reversible, no activation needed to work
      - Ticagrelor (Brilinta)
        - More rapid onset, ≥ than clopidogrel
      - Cangrelor
        - Immediate onset – 1 hour
  - Prostaglandin Analogues (PGI2)
    - Treprostinil (Remoodulin)
  - Thromboxane Inhibitors
    - Dipyridamole
      - Blocks AMP BD, inhibit Platelet activation
  - GP IIb/IIIa antagonists
    - Abciximab (ReoPro)
      - PCI w/o ADPRA, not renally cleared
    - Eptifibatide (Integrilin)
    - Tirofiban (Aggrastat)
      - High risk unstable angina
  - PAR-1 Antagonist
    - Vorapaxar
  - Phosphodiesterase inhibitor
    - Intermittent claudication
    - Cilostazol
  - Combos
    - Aspirin + Clopidogrel
      - 4 weeks after bare metal stent
      - 6 months after drug eluting stent
      - Unstable angina
    - Aspirin + Prasugrel
      - Patients undergoing PCI
- 2) Anticoagulants
  - A) Vitamin K Antagonists
    - Warfarin (Coumadin)
      - MOA: Vitamin K epoxide reductase inhibitor
        - Inhibits Prothrombin (II), VII, IX, X, C, S
      - Needs to be bridged for 5 days if HR (most surgeries)
        - Bridge when HR or valves: Use LMWH when INR \<2
      - Monitored via INR ≥ PT, 97% bound to albumin
      - Can be used in breastfeeding
      - Reversal: INR ≥ 10 = oral vit k
        - + bleeding = 4F-PCC (works in minutes), IV vitamin K (12-24hrs, risk of anaphylaxis) ≥ FFP
          - Four-Factor Prothrombin Complex (4F-PCC)
            - Contains Factors II, VII, IX, and X as a lyophilized powder
          - Indicated in brain hemorrhage
        - No bleeding, INR 4.5-10: withhold
        - No bleeding, INR 3-4.5: watch and wait
      - CI: Pregnancy (crosses placenta)
        - Vit k, nasal hypoplasia, stippled epiphyses in first trimester
      - Warfarin-Induced Skin Necrosis
        - 2-5 days after initiation
        - Well demarcated, center lesion necrotic, thrombi in microvasculature
        - Protein c or s def, initiation
        - Treatment
          - Vitamin K, heparin, discontinue warfatin
          - +/- Protein C (concentrated or in FFP)
      - Warfarin Metabolism
        - CYP450 Inhibitors (Increased Warfarin effect)
          - Risk of Hemorrhage
          - Acetaminophen, NSAIDs, Metronidazole, Amiodarone, Cimetidine, Cranberry Juice, Ginkgo biloba, VitE, omeprazole, Thyroid hormone, SSRIs
        - CYP450 Inducers (Decreased Warfarin effect)
          - Risk of Thrombosis
          - Carbamazepine, Phenytoin, Ginseng, St. John Wort, OCPs, Phenobarbital, Rifampin, Spinach/Sprouts (Vitamin K)
      - INR Management
        - INR \<5 + none or minimal bleeding:
          - Hold warfarin for 1-2 days or decrease dose
        - INR 5-9 + none or minimal bleeding:
          - Hold warfarin and resume when INR is therapeutic, give 1-2.5mg oral VitK if increased risk of bleeding
        - INR ≥9 + none or minimal bleeding
          - Hold warfarin and give 2.5-5mg oral VitK
        - Any serious or life-threatening bleeding:
          - Hold warfarin, five 10mg IV Vitk, FFP, recombinant factor VIIa, or PCC
  - B) Factor Xa Inhibitors
    - I) Heparins/Glycosaminoglycans/Binds Antithrombin
      - A) Unfractionated Heparin (UFH) (Parenteral)
        - Must monitor using aPTT
        - Dose dependent, saturable, weaker binding to endothelial, macrophage, hbpps
        - Activates Antithrombin (III) ≥ binds fibrin
          - Accelerates Antithrombin clot inhibition
            - Inhibiting Thrombin and Factor Xa
          - Forms thrombin-antithrombin complex
          - Can cause platelet activation?
        - Causes TFPI release
        - Neutralized by PF4 (platelet rich thrombi)
        - Heparin Inducted Thrombocytopenia (HIT)
        - Protamine sulfate (1mg to 100U) to reverse
        - SE: Osteoporosis, increase bilirubin
      - B) Low-Molecular-Weight Heparin (LMWH) (Parenteral)
        - Enoxaparin (Lovenox)
          - Made from Unfractionated Heparin
          - Greater capacity to potentiate factor Xa inhibition than thrombin due to being a short chain (2:1 – 4:1 Xa to iia)
        - VTE + Cancer
        - Dose independent, renal clearance, rare resistance, no monitoring
        - Little aPTT affect, measure anti-Xa to monitor (Heparin-Xa)
          - Every 4 hours
          - Obesity, renal insufficiency, pregnant, valves
      - C) Antithrombin III Inhibitors (Indirect Factor Xa inhibitors) (Parenteral)
        - Fondaparinux (Arixtra)
          - (smallest heparin chains) AT3
        - Can be used in surgical, ortho, VTE patients, only binds AT3, no thrombin rate inhibition, Xa only, renal cleared, can use in HIT, no antidote, no need to monitor
    - II) Direct Factor Xa Inhibitors
      - Factor Xa for monitoring
        - Stroke prevent, long term anticoagulation in nonvalvular afib
        - VTE treatment w/o cancer
      - Apixaban (Eliquis)
        - 10mg BID for ??
        - 5-5mg PO BID
      - Rivaroxaban (Xarelto)
        - 15mg BID for 21 days for VTE
        - 20mg PO daily with dinner
        - Renal Excretion
      - Edoxaban (Lixiana, Savaysa)
        - 60mg PO daily
  - C) Direct Thrombin Inhibitors (DTIs) (Parenteral)

      - Inhibit Thrombin (IIa)
    - Bivalent
      - Lepirudin/Desirudin (Revasc): Renal clearance, no metab
      - Bivalirudin (Angiomax)
        - Not renal, no metab
        - Activated clotting time, aptt
        - PCI instead of heparin
    - Univalent
      - Argatroban (acova)
        - Liver metabolism, not renal
        - HIT treatment
        - aPTT, prolongs INR
          - measure Factor X instead to monitor warfarin
      - Dabigatran (Pradaxa, Oral)
        - 150mg PO BID or 75mg PO BID if Crcl = 15-30
        - Direct Thrombin Inhibitor, Renally excreted, aPTT to monitor
          - PPIs decrease absorption
  - D) Other
    - Antithrombin III, Protein C
- 3) Fibrinolytic Agents
  - Degrade thrombi
  - Systemic administration: Acute MI, Acute Ischemic stroke, most Massive PE
  - Catheter based: Peripheral arterial thrombi, proximal deep veins
  - Drugs
    - All convert plasminogen to plasmin (zymogen to enzyme)
      - Degrades fibrin matrix
    - rtPA, alteplase
      - ibrin specific, plasminogen bound, activated (converts to plasmin)
      - higher fibrin affinity, works better around clots
      - \<75 w/\<6h of symptoms of Acute MI, Iv for 1-1.5h
    - Nonspecific – fibrin bound and circulating plasminogen activation – plasmin can cause lytic state
      - Streptokinase – no fibrin affinity
        - IV for Acute MI – reduce mortality
          - hypotension
      - Urokinase – not immunogenic, catheter lysis of thrombi
